Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development LifecycleUnusual Whales·5 hours ago
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderUnusual Whales·1 day ago, 06:03 AMCAMP0.00%
REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0Earnings Watch·May 6 at 03:13 PMRVMDW-7.43%
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes | RVMD Stock NewsStockTitan·Apr 14 at 03:41 PMRVMD-2.24%RVMDW-7.43%
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?Barchart Option·Apr 13 at 02:03 PMRVMD-2.24%RVMDW-7.43%
REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 0Earnings Watch·Feb 25 at 03:20 PMRVMDW-7.43%
REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 0Earnings Watch·Feb 25 at 03:08 PMRVMDW-7.43%
U.S. stock market close | Nasdaq slightly up 0.16%, Intel leads the semiconductor sectorMarket Pulse·Jan 7 at 03:13 PMINTC-5.86%NVDA+0.25%
REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0Earnings Watch·Nov 5, 2025 at 03:27 PMRVMDW-7.43%
REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -1.31Earnings Watch·Aug 6, 2025 at 03:15 PMRVMDW-7.43%
REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.13Earnings Watch·May 7, 2025 at 03:15 PMRVMDW-7.43%
